北京大学学报(医学版) ›› 2025, Vol. 57 ›› Issue (2): 400-402. doi: 10.19723/j.issn.1671-167X.2025.02.029

• 病例报告 • 上一篇    下一篇

垂体瘤合并肝硬化患者生长激素反常升高1例

王燕磊, 段敏, 肖建中, 赵文惠△()   

  1. 清华大学附属北京清华长庚医院,清华大学临床医学院, 北京 102218
  • 收稿日期:2021-10-11 出版日期:2025-04-18 发布日期:2025-04-12
  • 通讯作者: 赵文惠 E-mail:zwha01637@btch.edu.cn

Abnormal elevation of growth hormone in patients with pituitary adenoma combined with cirrhosis: A case report

Yanlei WANG, Min DUAN, Jianzhong XIAO, Wenhui ZHAO△()   

  1. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
  • Received:2021-10-11 Online:2025-04-18 Published:2025-04-12
  • Contact: Wenhui ZHAO E-mail:zwha01637@btch.edu.cn

RICH HTML

  

关键词: 垂体瘤, 肝硬化, 葡萄糖生长激素抑制试验

Abstract:

The oral glucose growth hormone suppression test is commonly used in the clinical diagnosis of acromegaly, but its results can be influenced by a variety of factors. This case report discusses a patient with a pituitary tumor and concurrent liver cirrhosis, highlighting the complexities in interpreting test results under such conditions. The patient, a 54-year-old male, presented with blurred vision as his primary complaint. Notably, the physical examination revealed no changes in facial features, no enlargement of hands or feet, and no other symptoms typically associated with acromegaly, which might otherwise suggest excessive growth hormone activity. Magnetic Resonance Imaging (MRI) of the pituitary gland indicated that the gland was within normal size parameters, but a small low-intensity lesion mea-suring approximately 3 mm×2 mm identified. This finding was consistent with a pituitary microadenoma. The patient's fasting growth hormone levels were significantly elevated at 8.470 μg/L, compared with the normal range of less than 2.47 μg/L. Conversely, fasting insulin-like growth factor-1 (IGF-1) levels were notably low, recorded at 41 and 52 μg/L, whereas the normal range for a person of his age was between 87 and 234 μg/L. Other pituitary hormones, including those regulating the thyroid, adrenal cortex, and sex hormones, were found to be within normal ranges. Despite this, during the glucose growth hormone suppression test, an abnormal elevation of growth hormone was observed. To investigate further, the patient was administered branched-chain amino acids, and the suppression test was repeated. However, the abnormal elevation of growth hormone persisted, indicating a failure to normalize the response. Given the patient's lack of clinical signs typically associated with elevated growth hormone secretion, the history of liver cirrhosis became a significant consideration. The disparity between elevated growth hormone levels and reduced IGF-1 levels suggested that the pituitary lesion was a non-functional adenoma rather than a source of excess hormone production. Consequently, it was concluded that the abnormal response of growth hormone to the glucose suppression test was likely related to the patient's liver cirrhosis. In addition to chronic liver disease, various other conditions could influence the results of the oral glucose tolerance growth hormone suppression test. According to the literature, factors such as puberty, diabetes, anorexia nervosa, and protein malnutrition could also affect test outcomes. These conditions could cause similar abnormalities in growth hormone dynamics, complicating the diagnosis. Therefore, clinicians must be vigilant and consider these potential influences when interpreting test results.For an accurate diagnosis of acromegaly, it is essential to combine clinical symptoms, detailed medical history, and imaging studies. The presence of conditions like liver cirrhosis should prompt careful interpretation of the test results, ensuring that other contributing factors are not overlooked. This comprehensive approach is crucial to avoid misdiagnosis and to ensure that appropriate treatment strategies are implemented based on a thorough understanding of the patient's overall health status.

Key words: Pituitary neoplasms, Liver cirrhosis, Glucose tolerance test

中图分类号: 

  • R736.4

表1

患者葡萄糖生长激素抑制试验"

Items 0 h 0.5 h 1 h 1.5 h 2 h
Glucose/(mmol/L) 4.34 17.80 17.54 9.88 3.58
Insulin/(mU/L) 10.18 >300.00 >300.00 >300.00 93.60
C-peptide/(μg/L) 0.90 9.78 11.01 14.14 7.18
Growth hormone/(μg/L) 2.42 10.82 9.83 5.31 2.33

表2

输注支链氨基酸同时复查葡萄糖生长激素抑制试验"

Items 0 h 0.5 h 1 h 2 h 3 h
Glucose/(mmol/L) 5.02 13.08 17.96 3.85 1.65
Insulin/(mU/L) 14.40 37.84 >300.00 223.59 23.84
C-peptide/(μg/L) 1.01 2.27 12.45 11.42 2.93
Growth hormone/(μg/L) 4.65 7.60 10.70 3.13 1.21
1 中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36 (9): 751- 760.
doi: 10.3760/cma.j.cn311282-20200706-00497
2 Ceccato F , Vedolin CK , Voltan G , et al. Paradoxical GH increase after oral glucose load in subjects with and without acromegaly[J]. J Endocrinol Invest, 2024, 47 (1): 213- 221.
3 母义明. 垂体瘤诊治进展[J]. 解放军医学杂志, 2017, 42 (7): 576- 582.
4 Aldahmani KM , Sreedharan J , Ismail MM , et al. Prevalence and characteristics of sellar masses in the city of Al Ain, United Arab Emirates: 2010 to 2016[J]. Ann Saudi Med, 2020, 40 (2): 105- 112.
doi: 10.5144/0256-4947.2020.105
5 Gorbacheva AM , Przhiyalkovskaya EG , Azizyan VN , et al. An ovarian hyperstimulation syndrome caused by gonadotropinoma in a young woman[J]. Probl Endokrinol (Mosk), 2019, 65 (4): 278- 288.
doi: 10.14341/probl10178
6 闵佳, 丁惠国, 闫惠萍, 等. 肝炎后肝硬化患者生长激素: 胰岛素样生长因子轴变化及其临床意义[J]. 中华国际医学杂志, 2002, 2 (4): 311- 313.
7 刘哲, 刘永雄, 冯玉泉. 生长激素与肝脏[J]. 中华肝胆外科杂志, 2001, 7 (1): 59- 61.
8 钱学敏, 李继强. 生长激素抵抗和肝硬化[J]. 国际消化病杂志, 2001, 21 (2): 97- 100.
9 Martina V , Tagliabue M , Bruno GA , et al. The altered plasma amino acid pattern is responsible for the paradoxical growth hormone response to the oral glucose tolerance test in liver cirrhosis[J]. Clin Endocrinol (Oxf), 1998, 48 (2): 175- 180.
doi: 10.1046/j.1365-2265.1998.3701183.x
10 Atquet V , Alexopoulou O , Maiter D . Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load[J]. Eur J Endocrinol, 2021, 185 (2): 313- 321.
doi: 10.1530/EJE-21-0324
11 Umahara M , Okada S , Ohshima K , et al. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly[J]. Endocr J, 2003, 50 (5): 643- 650.
12 Hage M , Chaligne R , Viengchareun S , et al. Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas[J]. J Clin Endocrinol Metab, 2019, 104 (5): 1777- 1787.
13 Oba-Yamamoto C , Kameda H , Miyoshi H , et al. Acromegaly cases exhibiting increased growth hormone levels during oral glucose loading with preadministration of dipeptidyl peptidase-4 inhibitor[J]. Intern Med, 2021, 60 (15): 2375- 2383.
14 Hage M , Kamenicky P , Chanson P . Growth hormone response to oral glucose load: From normal to pathological conditions[J]. Neuroendocrinology, 2019, 108 (3): 244- 255.
[1] 王明,李辉,王静,高嵩. 利用X射线衍射增强成像技术诊断肝纤维化[J]. 北京大学学报(医学版), 2018, 50(5): 899-904.
[2] 刘红虹, 福军亮, 徐军, 罗生强 , 刘振文, 王福生. 123例原发性胆汁性肝硬化临床表现与自身抗体谱[J]. 北京大学学报(医学版), 2013, 45(2): 233-.
[3] 范晓棠, 罗兰, 张立国, 哈丽达·夏尔甫哈孜, 罗超, 陈新春, 何方平 . 4 023例新疆地区肝硬化患者特征分析[J]. 北京大学学报(医学版), 2012, 44(5): 808-811.
[4] 肖华, 陈进伟, 谢希, 刘一鸣, 李芬. 自身抗体检测在原发性胆汁性肝硬化诊断中的价值[J]. 北京大学学报(医学版), 2012, 44(2): 209-214.
[5] 蒋媛嫄, 王霄英, 郭雪梅, 蒋学祥. 磁共振成像与多排探测器CT对乙型肝炎肝硬化背景上小肝癌诊断价值的比较研究[J]. 北京大学学报(医学版), 2010, 42(6): 767-772.
[6] 辛殿祺, 朱绪辉, 来永庆, 由然, 那彦群, 郭应禄, 毛泽斌. 雄激素调控前列腺癌中PTTG1表达的研究[J]. 北京大学学报(医学版), 2005, 37(6): 638-640.
[7] 戴芸, 梁颖慧, 谢鹏雁, 陈宝雯, 刘新光. 42例原发性胆汁性肝硬化临床分析[J]. 北京大学学报(医学版), 2005, 37(4): 410-414.
[8] 吴赤红, 徐小元, 陆海英, 于岩岩, 王贵强. 原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征患者的临床和病理分析[J]. 北京大学学报(医学版), 2004, 36(6): 609-611.
[9] 翁山耕, 冷希圣, 魏玉华, 彭吉润, 郑恩涛, 程继华, 张佑彬, 吕建锋, 杜如昱. 改良法大鼠肝星状细胞的分离培养及鉴定[J]. 北京大学学报(医学版), 2001, 33(1): 83-86.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!